Report Preview

Eczema Therapeutics Market

The global eczema therapeutics market size was valued at USD 15,000 million in 2021 and is projected to reach around USD 35,000 million in 2030 exhibiting a CAGR of 11% in the forecasted period. The rising prevalence of atopic dermatitis is anticipated to upsurge the market growth. Additionally, favourable reimbursement policies, growing awareness for the treatment and management of eczema, increasing partnerships of major players will support in creating profitable openings for market players. However, side effects related to corticosteroids will be a major challenge impacting negatively the global market growth.

The increased prevalence of atopic dermatitis is boosting the global market growth. There is a high incidence of eczema across the globe. Eczema can be produced by several factors, containing exposure to allergens such as skin irritations such as few fabrics, household cleaners, or soaps; pollen, peanuts, or pet dander; dry skin; stress; and infections. A large patient pool offers substantial opportunities for the growth of the market. Asia has a huge patient population with atopic dermatitis, with China, India, and Japan being the top revenue funders.

The COVID-19 pandemic considerably impacted the eczema therapeutics market. According to an NCBI article issued in March 2022, atopic dermatitis is related with an augmented risk of COVID-19 infection. Also, numerous initiatives were announced to manage COVID-19 patients suffering from atopic dermatitis. For example, as per a June 2020 update, the SECURE-AD Patient survey is intended to help apprehend how the coronavirus pandemic (COVID-19) affects people with atopic eczema. This survey stimulated the patient population with atopic dermatitis globally to participate and report their understanding with COVID-19 infection. Such studies collecting the difficulties in patients with atopic dermatitis diseased with COVID-19 provided the understanding and permissibility for numerous treatments of atopic dermatitis, thus impacting the market growth. Therefore, the pandemic considerably impacted the market’s growth throughout the COVID peak periods. Though, after the reduction of strict regulations on patient conferences at healthcare centers, the present market scenario is anticipated to drive growth through the forecasted period.

The significant factors fuelling the market’s growth are the growing burden of allergic reactions, an important role played by food allergy, and rising environmental pollution. The increasing burden of allergic reactions, with a substantial role in food allergies, is motivating the market’s growth. For instance, Food Allergy Research and Education (FARA) report in 2020 expected that 32 million United States residents have food allergies, containing 5.6 million children under age 18. Approximately 40% of children with food allergies are sensitive to more than one food.

Indication Insights

The indication segment is atopic dermatitis, contact dermatitis, and others. During the forecasted period, the atopic dermatitis segment will be a substantial provider to market growth during the forecasted period. Atopic dermatitis is a chronic, highly pruritic inflammatory skin disorder and is among the most common skin diseases in children. It generally onsets in infantile and often gets slighter or vanishes by adulthood. The development of this segment is accredited to factors such as a strong pipeline background, with several favourable product contenders in numerous stages of clinical development.

Region Insights

North America will dominate the eczema therapeutics market throughout the forecasted period. This region will account for about 40% of the market’s growth during the estimated period. The growth of this region is accredited to factors such as favourable reimbursement policies, increasing partnerships of key vendors with contract research organizations in developing nations, and high smart healthcare spending. Furthermore, market growth in this region will be quicker than the growth of the market in regions. The US is the important nation for the eczema therapeutics market in North America.

However, Asia Pacific is expected to record the fastest growth rate throughout the forecasted period. An upsurge in pro-health initiatives, acceptance of better treatments, and increase in consumer awareness are fuelling market growth in this region. Furthermore, the increasing prevalence of atopic dermatitis, growing demand for cost-effective treatment, and rising population significantly contribute to market growth. Asia Pacific markets such as Australia, China, Korea, and Taiwan already have healthcare compensation systems that offer complete analysis for molecular diagnostic tests.

Key Companies Insights

The market for Eczema therapeutics is moderately competitive. With the rising applications of Eczema therapeutics, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Eczema therapeutics market, ultimately boosting the market growth. Some of the key companies working in the global Eczema therapeutics market include:

• Pfizer Inc.
• Sanofi
• AbbVie Inc.
• GALDERMA LABORATORIES, L.P.
• Eli Lilly and Company (Dermira)
• Regeneron Pharmaceuticals Inc.
• LEO Pharma Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Novartis AG
• Incyte Corporation
• Other players

Some of the Recent Developments:

• In April 2021, AbbVie announced the postponement of sNDA for the evaluation of RINVOQ for atopic dermatitis teenage and adult patients.
• In September 2020, Kymera Therapeutics Inc. entered into a strategic collaboration with Sanofi to manufacture and commercialize its first-in-class protein degrader therapy aiming IRAK4 in patients with immune-inflammatory diseases such as atopic dermatitis. Such initiatives will fund the growth of the market emphasise during the forecasted period.

Segments

By Treatment

• Corticosteroids
• Emollients/Moisturizers
• Antihistamines
• Calcineurin inhibitors
• Antibiotics
• Immunomodulators
• Interleukin inhibitors

By Indication

• Atopic dermatitis
• Contact dermatitis
• Others

Distribution Channel

• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies

 By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt